【目的】DWP16001, a sodium-glucose cotransporter 2 inhibitor is currently been developed to treat type 2 diabetes mellitus. The purpose of this study was to evaluate the pharmacokinetic (PK) profiles of two formulations of enavogliflozin; the DWP16001 tablet A and the DWP16001 tablet B.【方法】A randomized, open-label, single dose, 2-period, 2-treatment, 2-sequence crossover study was conducted in healthy subjects. In each period, subjects received a single oral dose of the DWP16001 tablet A or the DWP16001 tablet B (both tablets contained 0.3 mg of DWP16001). Serial blood samples were collected up to 72 hours for PK analysis. 【結果・考察】The plasma DWP16001 concentration-time profiles of two formulations were similar. For the DWP16001 tablet B, the C_max and the AUC_last of DWP16001 were 4.35 ± 0.76 (mean ± standard deviation) mg/L and 25.40 ± 7.57 h*ng/mL, and their corresponding values for the DWP16001 tablet A were 4.48 ± 1.06 mg/L and 24.72 ± 6.97 h*mg/L, respectively. The geometric mean ratios (90% confidence intervals) of the DWP16001 tablet B to the DWP16001 tablet A for _max and AUC_last were 1.0229 (0.9765 － 1.0716) and 0.9881 (0.9542 － 1.0232), respectively, which met the bioequivalence criteria of Korean regulatory agency.【結論】The DWP16001 tablet B had similar PK profiles compared to a the DWP16001 tablet A. Therefore, the DWP16001 tablet B can be administered in place of the DWP16001 tablet A.